The Role of Oncolytic Viruses in the Treatment of Melanoma

Claire Audrey Y. Bayan, Adriana T. Lopez, Robyn D. Gartrell, Kimberly M. Komatsubara, Margaret Bogardus, Nisha Rao, Cynthia Chen, Thomas D. Hart, Thomas Enzler, Emanuelle M. Rizk, Jaya Sarin Pradhan, Douglas K. Marks, Larisa J. Geskin, Yvonne M. Saenger

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Purpose of Review: Oncolytic virotherapy is a new approach to the treatment of cancer and its success in the treatment of melanoma represents a breakthrough in cancer therapeutics. This paper provides a review of the current literature on the use of oncolytic viruses (OVs) in the treatment of melanoma. Recent Findings: Talimogene laherparepvec (T-VEC) is the first OV approved for the treatment of melanoma and presents new challenges as it enters the clinical setting. Several other OVs are at various stages of clinical and pre-clinical development for the treatment of melanoma. Reports from phase Ib-III clinical trials combining T-VEC with checkpoint blockade are encouraging and demonstrate potential added benefit of combination immunotherapy. Summary: OVs have recently emerged as a standard treatment option for patients with advanced melanoma. Several OVs and therapeutic combinations are in development. Immunooncolytic virotherapy combined with immune checkpoint inhibitors is promising for the treatment of advanced melanoma.

Original languageEnglish (US)
Article number80
JournalCurrent oncology reports
Issue number10
StatePublished - Oct 1 2018
Externally publishedYes


  • Biosafety
  • Combination therapy
  • Immunotherapy
  • Melanoma
  • Oncolytic viral therapy
  • Oncolytic virus
  • Talimogene laherparepvec (T-VEC)
  • Tumor microenvironment

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'The Role of Oncolytic Viruses in the Treatment of Melanoma'. Together they form a unique fingerprint.

Cite this